Veterinary Medicines

Zoletil Vet pulver og væske til injeksjonsvæske, oppløsning

Authorised
  • Tiletamine hydrochloride
  • Zolazepam hydrochloride
Download as PDF

Product identification

Medicine name:
Zoletil Vet pulver og væske til injeksjonsvæske, oppløsning
Active substance:
  • Tiletamine hydrochloride
  • Zolazepam hydrochloride
Target species:
  • Dog
  • Cat
Route of administration:
  • Intravenous use
  • Intramuscular use

Product details

Active substance and strength:
  • Tiletamine hydrochloride
    125.00
    milligram(s)
    /
    1.00
    Vial
  • Zolazepam hydrochloride
    125.00
    milligram(s)
    /
    1.00
    Vial
Pharmaceutical form:
  • Powder and solution for solution for injection
Withdrawal period by route of administration:
  • Intravenous use
    • Dog
    • Cat
  • Intramuscular use
    • Cat
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN01AX99
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Available in:
  • Norway
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 00-07871
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 16/02/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."